Patents by Inventor Kamon Shirakawa
Kamon Shirakawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11685788Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.Type: GrantFiled: May 1, 2020Date of Patent: June 27, 2023Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Patent number: 11117974Abstract: The present invention provides anti-presepsin polyclonal antibodies specifically binding to a peptide comprising an amino acid sequence of SEQ ID NO: 1. As a result, anti-presepsin polyclonal antibodies which have less variation in measured values between lot-to-lot differences of antibodies compared to S68 antibodies and thus suitable anti-presepsin polyclonal antibodies for presepsin measurement are provided.Type: GrantFiled: August 25, 2015Date of Patent: September 14, 2021Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Patent number: 11084883Abstract: The present invention provides anti-presepsin polyclonal antibodies specifically binding to a peptide comprising an amino acid sequence of SEQ ID NO: 1. As a result, anti-presepsin polyclonal antibodies which have less variation in measured values between lot-to-lot differences of antibodies compared to S68 antibodies and thus suitable anti-presepsin polyclonal antibodies for presepsin measurement are provided.Type: GrantFiled: August 25, 2015Date of Patent: August 10, 2021Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Patent number: 11041864Abstract: Disclosed is a prediction method for the prognosis of sepsis comprising measuring an sCD14-ST level in a sample. sCD14-ST, to be measured in the present invention, is a marker superior to procalcitonin, known as a marker to predict the prognosis in sepsis patients.Type: GrantFiled: January 10, 2012Date of Patent: June 22, 2021Assignees: LSI MEDIENCE CORPORATION, MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Takeshi Matsuya, Yoshikazu Okamura, Ralf Thomae, Eberhard Spanuth, Boris Ivandic, Kamon Shirakawa, Shigeatsu Endo
-
Publication number: 20210107990Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.Type: ApplicationFiled: May 1, 2020Publication date: April 15, 2021Applicant: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Patent number: 10676532Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.Type: GrantFiled: March 8, 2018Date of Patent: June 9, 2020Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Publication number: 20180237537Abstract: The present invention provides anti-presepsin polyclonal antibodies specifically binding to a peptide comprising an amino acid sequence of SEQ ID NO: 1. As a result, anti-presepsin polyclonal antibodies which have less variation in measured values between lot-to-lot differences of antibodies compared to S68 antibodies and thus suitable anti-presepsin polyclonal antibodies for presepsin measurement are provided.Type: ApplicationFiled: August 25, 2015Publication date: August 23, 2018Applicant: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon SHIRAKAWA
-
Patent number: 10054585Abstract: Methods for detecting respiratory infection associated with bacterial infection are described, in which the values of soluble CD14 antigen subtype (“sCD14-ST”) in the urine sample can be used to select a patient with a respiratory infection to whom antibiotic can be beneficially administered. The methods of this disclosure can also be used to determine the timing for ending administration of the antibiotic to the patient with respiratory infection associated with bacterial infection.Type: GrantFiled: February 19, 2016Date of Patent: August 21, 2018Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Publication number: 20180201688Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.Type: ApplicationFiled: March 8, 2018Publication date: July 19, 2018Applicant: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon SHIRAKAWA
-
Patent number: 10024869Abstract: According to the methods for detecting respiratory infection associated with bacterial infection of the present invention, the values of soluble CD14 antigen subtype (“sCD14-ST”) in the blood sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered. The methods of this disclosure can also be used to determine the timing for ending administration of the antibiotic to the patient with respiratory infection.Type: GrantFiled: February 11, 2016Date of Patent: July 17, 2018Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Patent number: 9951142Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.Type: GrantFiled: February 25, 2015Date of Patent: April 24, 2018Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Publication number: 20160169889Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in that a measured value of sCD14-ST in urine is used as an indication.Type: ApplicationFiled: February 19, 2016Publication date: June 16, 2016Applicant: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Publication number: 20160161506Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in which a measured value of sCD14-ST in blood is used as an indication.Type: ApplicationFiled: February 11, 2016Publication date: June 9, 2016Inventor: Kamon Shirakawa
-
Patent number: 9297802Abstract: According to the method for detecting respiratory infection associated with bacterial infection of the present invention, the measured value of soluble CD14 antigen subtype (“sCD14-ST) in the urine sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered.Type: GrantFiled: May 18, 2012Date of Patent: March 29, 2016Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Patent number: 9291631Abstract: According to the method for detecting respiratory infection associated with bacterial infection of the present invention, the measured value of soluble CD14 antigen subtype (“sCD14-ST) in the blood sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered.Type: GrantFiled: May 18, 2012Date of Patent: March 22, 2016Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Publication number: 20150239982Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.Type: ApplicationFiled: February 25, 2015Publication date: August 27, 2015Applicant: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon SHIRAKAWA
-
Publication number: 20140213507Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in which a measured value of sCD14-ST in blood is used as an indication.Type: ApplicationFiled: May 18, 2012Publication date: July 31, 2014Inventor: Kamon Shirakawa
-
Publication number: 20140171359Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in that a measured value of sCD14-ST in urine is used as an indication.Type: ApplicationFiled: May 18, 2012Publication date: June 19, 2014Inventor: Kamon Shirakawa
-
Publication number: 20140044723Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.Type: ApplicationFiled: July 24, 2013Publication date: February 13, 2014Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
-
Publication number: 20130288276Abstract: Disclosed is a prediction method for the prognosis of sepsis comprising measuring an sCD14-ST level in a sample. sCD14-ST, to be measured in the present invention, is a marker superior to procalcitonin, known as a marker to predict the prognosis in sepsis patients.Type: ApplicationFiled: January 10, 2012Publication date: October 31, 2013Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., Mitsubishi Chemical Medience CorporationInventors: Takeshi Matsuya, Yoshikazu Okamura, Ralf Thomae, Eberhard Spanuth, Boris Ivandic, Kamon Shirakawa, Shigeatsu Endo